Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor

Journal of Medicinal Chemistry

Volumn 56, Issue 17, 2013, Pages 6901-6916

  Perrey, David A ^a   German, Nadezhda A ^a   Gilmour, Brian P ^a   Li, Jun Xu ^b   Harris, Danni L ^a   Thomas, Brian F ^a   Zhang, Yanan ^a  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [(3,4 DIMETHOXYPHENYL)METHYL] 6 METHOXY 7 (2,2,2 TRIFLUOROETHOXY) 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL] N (PYRIDIN 3 YLMETHYL) ACETAMIDE; COCAINE; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM MOBILIZATION; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG PREFERENCE; DRUG SYNTHESIS; DRUG TOLERANCE; NONHUMAN; PHARMACOPHORE; PLACE PREFERENCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT;

ANIMALS; COCAINE; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES;

EID: 84884214425     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400720h     Document Type: Article

References (50)

1. de Lecea, L.; Kilduff, T. S.; Peyron, C.; Gao, X.; Foye, P. E.; Danielson, P. E.; Fukuhara, C.; Battenberg, E. L.; Gautvik, V. T.; Bartlett, F. S., 2nd; Frankel, W. N.; van den Pol, A. N.; Bloom, F. E.; Gautvik, K. M.; Sutcliffe, J. G. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 322-327
2. Sakurai, T.; Amemiya, A.; Ishii, M.; Matsuzaki, I.; Chemelli, R. M.; Tanaka, H.; Williams, S. C.; Richardson, J. A.; Kozlowski, G. P.; Wilson, S.; Arch, J. R.; Buckingham, R. E.; Haynes, A. C.; Carr, S. A.; Annan, R. S.; McNulty, D. E.; Liu, W. S.; Terrett, J. A.; Elshourbagy, N. A.; Bergsma, D. J.; Yanagisawa, M. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior Cell 1998, 92, 573-585
3. Gotter, A. L.; Webber, A. L.; Coleman, P. J.; Renger, J. J.; Winrow, C. J. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology Pharmacol. Rev. 2012, 64, 389-420
4. Kukkonen, J. P. Physiology of the orexinergic/hypocretinergic system: a revisit in 2012 Am. J. Physiol. 2013, 304, C2-32
5. Date, Y.; Ueta, Y.; Yamashita, H.; Yamaguchi, H.; Matsukura, S.; Kangawa, K.; Sakurai, T.; Yanagisawa, M.; Nakazato, M. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 748-753
6. Nambu, T.; Sakurai, T.; Mizukami, K.; Hosoya, Y.; Yanagisawa, M.; Goto, K. Distribution of orexin neurons in the adult rat brain Brain Res. 1999, 827, 243-260
7. Peyron, C.; Tighe, D. K.; van den Pol, A. N.; de Lecea, L.; Heller, H. C.; Sutcliffe, J. G.; Kilduff, T. S. Neurons containing hypocretin (orexin) project to multiple neuronal systems J. Neurosci. 1998, 18, 9996-10015
8. Sakurai, T. Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis Sleep Med. Rev. 2005, 9, 231-241
9. Sutcliffe, J. G.; de Lecea, L. The hypocretins: Setting the arousal threshold Nat. Rev. Neurosci. 2002, 3, 339-349
10. Marcus, J. N.; Aschkenasi, C. J.; Lee, C. E.; Chemelli, R. M.; Saper, C. B.; Yanagisawa, M.; Elmquist, J. K. Differential expression of orexin receptors 1 and 2 in the rat brain J. Comp. Neurol. 2001, 435, 6-25
11. Trivedi, P.; Yu, H.; MacNeil, D. J.; Van der Ploeg, L. H.; Guan, X. M. Distribution of orexin receptor mRNA in the rat brain FEBS Lett. 1998, 438, 71-75
12. Scammell, T. E.; Winrow, C. J. Orexin receptors: pharmacology and therapeutic opportunities Annu. Rev. Pharmacol. Toxicol. 2011, 51, 243-266
13. Kilduff, T. S.; Peyron, C. The hypocretin/orexin ligand-receptor system: Implications for sleep and sleep disorders Trends Neurosci. 2000, 23, 359-365
14. Ohno, K.; Sakurai, T. Orexin neuronal circuitry: Role in the regulation of sleep and wakefulness Front. Neuroendocrinol. 2008, 29, 70-87
15. Boutrel, B.; de Lecea, L. Addiction and arousal: The hypocretin connection Physiol. Behav. 2008, 93, 947-951
16. Harris, G. C.; Wimmer, M.; Aston-Jones, G. A role for lateral hypothalamic orexin neurons in reward seeking Nature 2005, 437, 556-559
17. Tsujino, N.; Sakurai, T. Orexin/hypocretin: A neuropeptide at the interface of sleep, energy homeostasis, and reward system Pharmacol. Rev. 2009, 61, 162-176
18. Harris, G. C.; Aston-Jones, G. Arousal and reward: A dichotomy in orexin function Trends Neurosci. 2006, 29, 571-577
19. Boutrel, B.; Kenny, P. J.; Specio, S. E.; Martin-Fardon, R.; Markou, A.; Koob, G. F.; de Lecea, L. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 19168-19173
20. Narita, M.; Nagumo, Y.; Hashimoto, S.; Narita, M.; Khotib, J.; Miyatake, M.; Sakurai, T.; Yanagisawa, M.; Nakamachi, T.; Shioda, S.; Suzuki, T. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine J. Neurosci. 2006, 26, 398-405
21. Hara, J.; Yanagisawa, M.; Sakurai, T. Difference in obesity phenotype between orexin-knockout mice and orexin neuron-deficient mice with same genetic background and environmental conditions Neurosci. Lett. 2005, 380, 239-242
22. Lawrence, A. J.; Cowen, M. S.; Yang, H. J.; Chen, F.; Oldfield, B. The orexin system regulates alcohol-seeking in rats Br. J. Pharmacol. 2006, 148, 752-759
23. Aston-Jones, G.; Smith, R. J.; Moorman, D. E.; Richardson, K. A. Role of lateral hypothalamic orexin neurons in reward processing and addiction Neuropharmacology 2009, 56, 112-121
24. Richards, J. K.; Simms, J. A.; Steensland, P.; Taha, S. A.; Borgland, S. L.; Bonci, A.; Bartlett, S. E. Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats Psychopharmacology 2008, 199, 109-117
25. Hollander, J. A.; Lu, Q.; Cameron, M. D.; Kamenecka, T. M.; Kenny, P. J. Insular hypocretin transmission regulates nicotine reward Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 19480-19485
26. Boss, C.; Brisbare-Roch, C.; Jenck, F. Biomedical application of orexin/hypocretin receptor ligands in neuroscience J. Med. Chem. 2009, 52, 891-903
27. Roecker, A. J.; Coleman, P. J. Orexin receptor antagonists: Medicinal chemistry and therapeutic potential Curr. Top. Med. Chem. 2008, 8, 977-987
28. Gatfield, J.; Brisbare-Roch, C.; Jenck, F.; Boss, C. Orexin receptor antagonists: A new concept in CNS disorders? ChemMedChem 2010, 5, 1197-1214
29. Kodadek, T.; Cai, D. Chemistry and biology of orexin signaling Mol. BioSyst. 2010, 6, 1366-1375
30. Smart, D.; Sabido-David, C.; Brough, S. J.; Jewitt, F.; Johns, A.; Porter, R. A.; Jerman, J. C. SB-334867-A: The first selective orexin-1 receptor antagonist Br. J. Pharmacol. 2001, 132, 1179-1182
31. Porter, R. A.; Chan, W. N.; Coulton, S.; Johns, A.; Hadley, M. S.; Widdowson, K.; Jerman, J. C.; Brough, S. J.; Coldwell, M.; Smart, D.; Jewitt, F.; Jeffrey, P.; Austin, N. 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor Bioorg. Med. Chem. Lett. 2001, 11, 1907-1910
32. Perrey, D. A.; Gilmour, B. P.; Runyon, S. P.; Thomas, B. F.; Zhang, Y. Diaryl urea analogues of SB-334867 as orexin-1 receptor antagonists Bioorg. Med. Chem. Lett. 2011, 21, 2980-2985
33. McElhinny, C. J., Jr.; Lewin, A. H.; Mascarella, S. W.; Runyon, S.; Brieaddy, L.; Carroll, F. I. Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: Possible confounding effects on in vivo and in vitro studies Bioorg. Med. Chem. Lett. 2012, 22, 6661-6664
34. Langmead, C. J.; Jerman, J. C.; Brough, S. J.; Scott, C.; Porter, R. A.; Herdon, H. J. Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor Br. J. Pharmacol. 2004, 141, 340-346
35. Jiang, R.; Song, X.; Bali, P.; Smith, A.; Bayona, C. R.; Lin, L.; Cameron, M. D.; McDonald, P. H.; Kenny, P. J.; Kamenecka, T. M. Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists Bioorg. Med. Chem. Lett. 2012, 22, 3890-3894
36. Stasi, P. L.; Rovati, L. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction. WIPO Patent WO2011006960, 2011.
37. Steiner, M. A.; Gatfield, J.; Brisbare-Roch, C.; Dietrich, H.; Treiber, A.; Jenck, F.; Boss, C. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist ChemMedChem 2013, 8, 898-903
38. Hirose, M.; Egashira, S.; Goto, Y.; Hashihayata, T.; Ohtake, N.; Iwaasa, H.; Hata, M.; Fukami, T.; Kanatani, A.; Yamada, K. N-Acyl 6,7-dimethoxy-1,2,3,4- tetrahydroisoquinoline: The first orexin-2 receptor selective non-peptidic antagonist Bioorg. Med. Chem. Lett. 2003, 13, 4497-4499
39. Koberstein, R.; Aissaoui, H.; Bur, D.; Clozel, M.; Fischli, W.; Jenck, F.; Mueller, C.; Nayler, O.; Sifferlen, T.; Treiber, A.; Weller, T. Tetrahydroisoquinolines as orexin receptor antagonists: Strategies for lead optimization by solution-phase chemistry Chimia 2003, 57, 270-275
40. Rice, K. C.; Brossi, A. Expedient synthesis of racemic and optically-active N-norreticuline and N-substituted and 6′-bromo-N- norreticulines J. Org. Chem. 1980, 45, 592-601
41. Nilsson, B. L.; Kiessling, L. L.; Raines, R. T. Staudinger ligation: A peptide from a thioester and azide Org. Lett. 2000, 2, 1939-1941
42. Caddick, S.; Afonso, C. A. M.; Candeias, S. X.; Hitchcock, P. B.; Jenkins, K.; Murtagh, L.; Pardoe, D.; Santos, A. G.; Treweeke, N. R.; Weaving, R. Synthesis of alpha-amino esters by dynamic kinetic resolution of alpha-haloacyl imidazolidinones Tetrahedron 2001, 57, 6589-6605
43. Neubauer, D. N. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia Curr. Opin. Investig. Drugs 2010, 11, 101-110
44. Verloop, A.; Tipker, J. In QSAR in Drug Design and Toxicology; Hadzi, D.; Jerman-Blazic, B., Eds.; Elsevier: Amsterdam, The Netherlands, 1987; Vol. 97.
45. Verloop, A. The STERIMOL Approach to Drug Design; Marcel Dekker: New York, 1987.
46. Kantola, A.; Villar, H. O.; Loew, G. H. Atom based parametrization for a conformationally dependent hydrophobic index J. Comput. Chem. 1991, 12, 681-689
47. Vainio, M. J.; Johnson, M. S. Generating conformer ensembles using a multiobjective genetic algorithm J. Chem. Inf. Model. 2007, 47, 2462-2474
48. Harris, D.; Clayton, T.; Cook, J.; Sahbaie, P.; Halliwell, R. F.; Furtmüller, R.; Huck, S.; Sieghart, W.; DeLorey, T. M. Selective influence on contextual memory: Physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the a5 subunit J. Med. Chem. 2008, 51, 3788-3803
49. Harris, D. L.; DeLorey, T. M.; He, X.; Cook, J. M.; Loew, G. H. Determinants of recognition of ligands binding to benzodiazepine receptor/GABA(A) receptors initiating sedation Eur. J. Pharmacol. 2000, 401, 271-287
50. Thorn, D. A.; An, X. F.; Zhang, Y.; Pigini, M.; Li, J. X. Characterization of the hypothermic effects of imidazoline I(2) receptor agonists in rats Br. J. Pharmacol. 2012, 166, 1936-1945